Med. praxi. 2025;22(5):362-365 | DOI: 10.36290/med.2025.059

Risk of rapid heart rate in atrial fibrillation - case report with discussion

prof. MUDr. ©těpán Havránek, Ph.D.
II. interní klinika kardiologie a angiologie 1. UK a VFN v Praze

The article presents a case study of a patient with untreated arterial hypertension and atrial fibrillation with a rapid ventricular response. The patient's condition was complicated by the development of heart failure due to arrhythmia-induced cardiomyopathy. The case study is followed by an analysis focusing on the appropriate treatment of arterial hypertension in patients with atrial fibrillation and the importance of heart rate-lowering therapy for the prevention and treatment of heart failure.

Keywords: atrial fibrillation, arterial hypertension, heart failure, rate-controlling therapy.

Received: July 23, 2025; Accepted: July 24, 2025; Published: December 1, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Havránek ©. Risk of rapid heart rate in atrial fibrillation - case report with discussion. Med. praxi. 2025;22(5):362-365. doi: 10.36290/med.2025.059.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 1.12.2026

    References

    1. ESC guidelines for management of atrial fibrillation. Eur Heart J. 2024;00:1-101.
    2. ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912-4018.
    3. Schneider M, Hua T, Bohm M, et al. Prevention of atrial fibrillation by renin-angiotensin system inhibition: a meta-analysis. J Am Coll Cardiol. 2010;55:2299-2307. Go to original source... Go to PubMed...
    4. Gopinathannair R, Etheridge S, Marchlinski F, et al. Arrhythmia-induced cardiomyopathies: mechanisms, recognition, and management. J Am Coll Cardiol. 2015;66:1714-1728. Go to original source... Go to PubMed...
    5. Jeong Y, Choi K, Song J, et al. Diagnostic approach and treatment strategy in tachycardia-induced cardiomyopathy. Clin Cardiol. 2008;31:172-178. Go to original source... Go to PubMed...
    6. Gentlesk P, Sauer W, Gerstenfeld E, et al. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18:9-14. Go to original source... Go to PubMed...
    7. De la Sierra A, et al. Ambulatory Blood Pressures in Hypertensive Patients Treated With One Antihypertensive Agent: Differences Among Drug Classes and Among Drugs Belonging to the Same Class. J Clin Hypertens. 2015;17(11):857-865. Go to original source... Go to PubMed...
    8. Wellstein A, et al. Affinity and selectivity of beta-adrenoceptor antagonists in vitro. J Cardiovasc Pharmacol. 1986;8(Suppl 11):36-40. Go to original source... Go to PubMed...
    9. Wellstein A, et al. Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy. Eur Heart J. 1987;8(Suppl M):3-8. Go to original source... Go to PubMed...
    10. 2023 ESH Guidelines for the management of arterial hypertension. 2023. J Hypertens. 2023;41(12):1874-2071.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.